|
Dec 15
|
3 Unstoppable Stocks to Buy Right Now
|
|
Dec 12
|
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
|
|
Dec 11
|
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
|
|
Dec 11
|
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
|
|
Dec 10
|
AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China
|
|
Dec 10
|
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
|
|
Dec 10
|
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
|
|
Dec 9
|
Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia
|
|
Dec 9
|
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
|
|
Dec 9
|
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
|
|
Dec 9
|
ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market
|
|
Dec 9
|
Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
|
|
Oct 25
|
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
|
|
Oct 25
|
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
|
|
Oct 25
|
Trending tickers: Tesla, Lloyds, Capri, Deckers and Mercedes-Benz
|
|
Oct 24
|
How CIOs gain employee buy-in on generative AI
|
|
Oct 23
|
How The Oncology Sector Is Set To Fuel AstraZeneca’s (AZN) Growth
|
|
Oct 22
|
AstraZeneca Receives CHMP's Approval for Wainzua in Europe
|
|
Oct 22
|
EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN
|
|
Oct 21
|
UK Stocks That May Be Trading Below Estimated Value
|